Accès à distance ? S'identifier sur le proxy UCLouvain
Predictors of disability worsening in clinically isolated syndrome.
Primary tabs
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès restreint |
Publication date | 2015 |
Language | Anglais |
Journal information | "Annals of Clinical and Translational Neurology" - Vol. 2, no.5, p. 479-491 (2015) |
Publisher | Wiley-Blackwell Publishing, Inc. (Hoboken) |
e-issn | 2328-9503 |
Publication status | Publié |
Affiliations |
UCL
- (SLuc) Service de neurologie UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire |
Links |
- Kappos L., Traboulsee A., Constantinescu C., Eralinna J. -P., Forrestal F., Jongen P., Pollard J., Sandberg-Wollheim M., Sindic C., Stubinski B., Uitdehaag B., Li D., Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS, 10.1212/01.wnl.0000237994.95410.ce
- Polman Chris H., O'Connor Paul W., Havrdova Eva, Hutchinson Michael, Kappos Ludwig, Miller David H., Phillips J. Theodore, Lublin Fred D., Giovannoni Gavin, Wajgt Andrzej, Toal Martin, Lynn Frances, Panzara Michael A., Sandrock Alfred W., A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, 10.1056/nejmoa044397
- Rudick Richard A., Stuart William H., Calabresi Peter A., Confavreux Christian, Galetta Steven L., Radue Ernst-Wilhelm, Lublin Fred D., Weinstock-Guttman Bianca, Wynn Daniel R., Lynn Frances, Panzara Michael A., Sandrock Alfred W., Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis, 10.1056/nejmoa044396
- Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), 10.1212/wnl.33.11.1444
- Ebers George C, Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, 10.1016/s0140-6736(98)03334-0
- Jacobs Lawrence, Rudick Richard, Simon Jack, Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics, 10.1016/s0165-5728(00)00232-0
- Noseworthy J. H., O'Brien P., Erickson B. J., Lee D., Sneve D., Ebers G. C., Rice G.P.A., Auty A., Hader W. J., Kirk A., Duquette P., Carter J., Francis G., Metz L., Shuster E., , The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis, 10.1212/wnl.51.5.1342
- Rudick R. A., Goodkin D. E., Jacobs L. D., Cookfair D. L., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Granger C. V., Simon J. H., Alam J. J., Simonian N. A., Campion M. K., Bartoszak D. M., Bourdette D. N., Braiman J., Brownscheidle C. M., Coats M. E., Cohan S. L., Dougherty D. S., Kinkel R. P., Mass M. K., Munschauer F. E., Priore R. L., Pullicino P. M., Scherokman B. J., Weistock-Guttman B., Whitham R. H., , Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis, 10.1212/wnl.49.2.358
- Wolinsky Jerry S., Narayana Ponnada A., O'Connor Paul, Coyle Patricia K., Ford Corey, Johnson Kenneth, Miller Aaron, Pardo Lillian, Kadosh Shaul, Ladkani David, , Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial, 10.1002/ana.21079
- , Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial, 10.1212/wnl.45.7.1277
- Liu C., Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts, 10.1136/jnnp.68.4.450
- Trojano M., Pellegrini F., Paolicelli D., Fuiani A., Zimatore G.B., Tortorella C., Simone I.L., Patti F., Ghezzi A., Zipoli V., Rossi P., Pozzilli C., Salemi G., Lugaresi A., Bergamaschi R., Millefiorini E., Clerico M., Lus G., Vianello M., Avolio C., Cavalla P., Lepore V., Livrea P., Comi G., Amato M.P., , Real-life impact of early interferonβ therapy in relapsing multiple sclerosis : Early IFNβ Treatment in RRMS, 10.1002/ana.21757
- MSBase http://www.msbase.org
- Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski J-P, MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis, 10.1177/1352458506070775
- Meyniel Claire, Spelman Timothy, Jokubaitis Vilija G., Trojano Maria, Izquierdo Guillermo, Grand’Maison François, Oreja-Guevara Celia, Boz Cavit, Lugaresi Alessandra, Girard Marc, Grammond Pierre, Iuliano Gerardo, Fiol Marcela, Cabrera-Gomez Jose Antonio, Fernandez-Bolanos Ricardo, Giuliani Giorgio, Lechner-Scott Jeannette, Cristiano Edgardo, Herbert Joseph, Petkovska-Boskova Tatjana, Bergamaschi Roberto, van Pesch Vincent, Moore Fraser, Vella Norbert, Slee Mark, Santiago Vetere, Barnett Michael, Havrdova Eva, Young Carolyn, Sirbu Carmen-Adella, Tanner Mary, Rutherford Michelle, Butzkueven Helmut, , Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome, 10.1371/journal.pone.0038661
- Comi Giancarlo, Filippi Massimo, Barkhof Frederik, Durelli Luca, Edan Gilles, Fernández Oscar, Hartung Hans-Peter, Seeldrayers Pierrette, Sørensen Per Soelberg, Rovaris Marco, Martinelli Vittorio, Hommes Otto R, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, 10.1016/s0140-6736(00)04725-5
- Confavreux C., Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, 10.1093/brain/awg081
- D’Alessandro Roberto, Vignatelli Luca, Lugaresi Alessandra, Baldin Elisa, Granella Franco, Tola Maria Rosaria, Malagù Susanna, Motti Luisa, Neri Walter, Galeotti Massimo, Santangelo Mario, Fiorani Laila, Montanari Enrico, Scandellari Cinzia, Benedetti Maria Donata, Leone Maurizio, Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study, 10.1007/s00415-013-6838-x
- Damasceno Alfredo, Von Glehn Felipe, Brandão Carlos Otávio, Damasceno Benito Pereira, Cendes Fernando, Prognostic indicators for long-term disability in multiple sclerosis patients, 10.1016/j.jns.2012.09.020
- Healy Brian C., Engler David, Gholipour Taha, Weiner Howard, Bakshi Rohit, Chitnis Tanuja, Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis, 10.1016/j.jns.2010.12.024
- Runmarker Björn, Andersen Oluf, Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up, 10.1093/brain/116.1.117
- Shirani Afsaneh, Zhao Yinshan, Karim Mohammad Ehsanul, Evans Charity, Kingwell Elaine, van der Kop Mia L., Oger Joel, Gustafson Paul, Petkau John, Tremlett Helen, Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis, 10.1001/jama.2012.7625
- Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G, Livrea P, Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events., 10.1136/jnnp.58.3.300
- Jacobs Lawrence D., Cookfair Diane L., Rudick Richard A., Herndon Robert M., Richert John R., Salazar Andres M., Fischer Jill S., Goodkin Donald E., Granger Carl V., Simon Jack H., Alam John J., Bartoszak David M., Bourdette Dennis N., Braiman Jonathan, Brownscheidle Carol M., Coats Michael E., Cohan Stanley L., Dougherty David S., Kinkel Revere P., Mass Michele K., Munschauer Frederick E., Priore Roger L., Pullicino Patrick M., Scherokman Barbara J., Weinstock-Guttman Bianca, Whitham Ruth H., , Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, 10.1002/ana.410390304
- Ebers G. C., Traboulsee A., Li D., Langdon D., Reder A. T., Goodin D. S., Bogumil T., Beckmann K., Wolf C., Konieczny A., , Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial, 10.1136/jnnp.2009.204123
- Uitdehaag Bernard, Constantinescu Cris, Cornelisse Peter, Jeffery Douglas, Kappos Ludwig, Li David, Sandberg-Wollheim Magnhild, Traboulsee Anthony, Verdun Elisabetta, Rivera Victor, Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study, 10.1177/1756285610391693
- Tremlett H., Yousefi M., Devonshire V., Rieckmann P., Zhao Y., , Impact of multiple sclerosis relapses on progression diminishes with time, 10.1212/wnl.0b013e3181c1e44f
- Brex Peter A., Ciccarelli Olga, O'Riordan Jonathon I., Sailer Michael, Thompson Alan J., Miller David H., A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis, 10.1056/nejmoa011341
- Fisniku L. K., Brex P. A., Altmann D. R., Miszkiel K. A., Benton C. E., Lanyon R., Thompson A. J., Miller D. H., Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, 10.1093/brain/awm329
- O'Riordan J., The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up, 10.1093/brain/121.3.495
- Tintore M., Rovira A., Rio J., Nos C., Grive E., Tellez N., Pelayo R., Comabella M., Sastre-Garriga J., Montalban X., Baseline MRI predicts future attacks and disability in clinically isolated syndromes, 10.1212/01.wnl.0000237354.10144.ec
- Comi Giancarlo, Martinelli Vittorio, Rodegher Mariaemma, Moiola Lucia, Leocani Letizia, Bajenaru Ovidiu, Carra Adriana, Elovaara Irina, Fazekas Franz, Hartung Hans-Peter, Hillert Jan, King John, Komoly Samuel, Lubetzki Catherine, Montalban Xavier, Myhr Kjell-Morten, Preziosa Paolo, Ravnborg Mads, Rieckmann Peter, Rocca Maria A, Wynn Daniel, Young Carolyn, Filippi Massimo, Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome, 10.1177/1352458512469695
- Kappos L., Polman C. H., Freedman M. S., Edan G., Hartung H. P., Miller D. H., Montalban X., Barkhof F., Bauer L., Jakobs P., Pohl C., Sandbrink R., , Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, 10.1212/01.wnl.0000237641.33768.8d
- , IM interferon -1a delays definite multiple sclerosis 5 years after a first demyelinating event, 10.1212/01.wnl.0000200778.65597.ae
- Kappos Ludwig, Freedman Mark S, Polman Chris H, Edan Gilles, Hartung Hans-Peter, Miller David H, Montalbán Xavier, Barkhof Frederik, Radü Ernst-Wilhelm, Bauer Lars, Dahms Susanne, Lanius Vivian, Pohl Christoph, Sandbrink Rupert, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study, 10.1016/s0140-6736(07)61194-5
- Kappos Ludwig, Freedman Mark S, Polman Chris H, Edan Gilles, Hartung Hans-Peter, Miller David H, Montalbán Xavier, Barkhof Frederik, Radü Ernst-Wilhelm, Metzig Carola, Bauer Lars, Lanius Vivian, Sandbrink Rupert, Pohl Christoph, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, 10.1016/s1474-4422(09)70237-6
- Trojano Maria, Paolicelli Damiano, Tortorella Carla, Iaffaldano Piero, Lucchese Guglielmo, Di Renzo Vita, D’Onghia Mariangela, Natural History of Multiple Sclerosis: Have Available Therapies Impacted Long-Term Prognosis?, 10.1016/j.ncl.2010.12.008
- Brown M. G., Kirby S., Skedgel C., Fisk J. D., Murray T. J., Bhan V., Sketris I. S., How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?, 10.1212/01.wnl.0000271884.11129.f3
- Trojano Maria, Pellegrini Fabio, Fuiani Aurora, Paolicelli Damiano, Zipoli Valentina, Zimatore Giovanni B., Di Monte Elisabetta, Portaccio Emilio, Lepore Vito, Livrea Paolo, Amato Maria Pia, New natural history of interferon-β-treated relapsing multiple sclerosis, 10.1002/ana.21102
- Trojano Maria, Liguori Maria, Paolicelli Damiano, Zimatore Giovanni Bosco, De Robertis Francesca, Avolio Carlo, Giuliani Fabrizio, Fuiani Aurora, Livrea Paolo, , Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy, 10.1191/1352458503ms948oa
- Trapp Bruce D., Peterson John, Ransohoff Richard M., Rudick Richard, Mörk Sverre, Bö Lars, Axonal Transection in the Lesions of Multiple Sclerosis, 10.1056/nejm199801293380502
- Kuhlmann T., Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, 10.1093/brain/awf235
- Lucchinetti Claudia F., Popescu Bogdan F.G., Bunyan Reem F., Moll Natalia M., Roemer Shanu F., Lassmann Hans, Brück Wolfgang, Parisi Joseph E., Scheithauer Bernd W., Giannini Caterina, Weigand Stephen D., Mandrekar Jay, Ransohoff Richard M., Inflammatory Cortical Demyelination in Early Multiple Sclerosis, 10.1056/nejmoa1100648
Bibliographic reference | Jokubaitis, Vilija G ; Spelman, Tim ; Kalincik, Tomas ; Izquierdo, Guillermo ; Grand'Maison, François ; et. al. Predictors of disability worsening in clinically isolated syndrome.. In: Annals of Clinical and Translational Neurology, Vol. 2, no.5, p. 479-491 (2015) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/171998 |